Tyme Technologies Inc. (TYME)

[Pt3]

er tomorrow should be good

[mickyboy59]

hi Alpha

very interesting article...thank you very much

maybe someone from you guys here is in that reddit group and can post this article....would be very interesting to see what happens.

very kind regards

mickyboy

[brown4321]

https://www.businesswire.com/news/home/20210203005199/en/TYME-Granted-U.S.-Patent-Claims-Covering-Use-of-TYME-19-to-Treat-COVID-19-Infections

[mcsharkey]

Excellent. Thakyou. P
Real pump before 3d Quarter Earnings. This is great

[Awl416]

Incredible

[AlphaStockNews]

$TYME is screaming for the top after announcing a patent related to COVID-19. This could be the next big short squeeze. https://cnafinance.com/tyme-stock-tyme-technologies-heads-up-on-covid-19-news/

[ChillingPenguin]

We did it boys!!!!! Hahahahhaa such a precious victory for all of us holding!!!

[mcsharkey]

Should be having 3d Qrtr Earnings by 11 Feb. We're in second month of last quarter and have been told to expect news on TYME-19 COVID Therapy.

2022 starts on April 1st for us. Some irony to that.

GKTUA

Here's link to 2nd Qrtr baseline.
https://www.bloomberg.com/press-releases/2020-11-12/tyme-provides-business-update-and-announces-second-quarter-fiscal-2021-financial-and-operating-results

[mcsharkey]

Apologies Hanomsn! Let me dig throuhh my crawl space a little later. And I' ll be back with you.

[mcsharkey]

Apologies Hanomsn! Let me dig throuhh my crawl space a little later. And I' ll be back with you.

[HANUMAN]

Mike, what's the scoop with Demurjian?

[mcsharkey]

Yeah Chillin' we got the same mindset, Proof of Concept on TYME 19 is my logical candidate for the spike. Then I get crazy with IF. Nice crazy. No news found. They haven'g update corporate presentation. Still at November's edition.

Along with TYME19 and breast cancer for the expansion check box, we have the Ewings Sarcoma effort. Havent found anything for us on Joseph Ahmed Foundation or PANCAN's Preciscion Promise. Just makingnstuff up in my head;).

GLTUA

[ChillingPenguin]

In my opinion, this is running due to Healthcare talk coming up this week with Biden. Cancer drugs and covid plays are rising as a whole, so Tyme is with them for the climb. Tyme-19 news due anytime 1H of 2021.

[HANUMAN]

What do you think is driving this?

[ChillingPenguin]

Hell yea!!! 2021 is our year to start this party!! So many stocks are flying, hard to keep up. Come on $9!!! Thanks for sharing that McSharky, always appreciate your input

[mcsharkey]

THIS IS COOL: New clinical trial just posted on 22nd for SM-88 being expanded to BREAST CANCER, as promised on earlier schedules. Sponsored by Georgetown University. We were doing well with breast cancer in a self-funded study that fell apart. Fired one of the founders for that. Red Bank Mike Demurjian who still has over 20 million shares. Selling them off every other week. His failure to dot i's and cross-tees one of the reasons funding on previous breast cancer study lost.

New Clinical Trial Identifier: NCT04720664[/quote]LINK[/quote]S'more news from weekend posts

Tyme Technologies – Consensus Indicates Potential 339.7% Upside
Broker Ratings
Charlotte Edwards
January 23, 2021
1:43 am
Tyme Technologies with ticker code (TYME) now have 2 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The target price ranges between 9.5 and 8 calculating the mean target price we have 8.75. Given that the stocks previous close was at 1.99 this is indicating there is a potential upside of 339.7%. The 50 day moving average now sits at 1.39 while the 200
LINK
Alrighty Then, GLTUA

[mcsharkey]

Trying to figure out the entries on that poster myself Hanuman. AHHHH, dislike the HUGE size right off. The conclusion of the Adverse Events ahhh, no serious adverse effects.

OK, good. Dunno. Way over my head, and difficult to navigate. This rise then flounder better than the fall.

All I got

Nameste'

[HANUMAN]

Seemed to be a lot of AE's (upper rt. of poster), and the conclusions didn't tell me a thing. But it may be just my ignorance.

[mcsharkey]

Huge volume aftermarket Gentlemen!
Tyme Technologies In (TYME)
2.09 ? 0.04 (1.95%)
Volume: 3,036,167 @01/19/21 7:57:28 PM EST

We'll see how this goes

[mcsharkey]

Detailed poster available here. https://www.tymeinc.com/data-publications/scientific-presentations/default.aspx

Huge in physical size. Legible with text sections copiable. Way too technical for me.

[sanderburwil]

$5+ ahead. Talk of ACSO and word spreading

[mcsharkey]

Published abstract on SM-88 TYME's self-sponsored PANC-88 TRIAL.

Had a draft of this last month. Nice to hve it published.
Link

[mcsharkey]

Published abstract on SM-88 TYME's self-sponsored PANC-88 TRIAL.

Had a draft of this last month. Nice to hve it published.
Link

[mcsharkey]

Vielen Dank Rode! I still can't crack it. I have a freebee account with OSCO. Worth everything I paid for.
Nuthin yet on company's investor site either.

[RodeKroet]

Abstracts seem to ve found in here: insert-text-here

[mcsharkey]

Virtual-Presentation-Scheduled for-tomorrow, Sunday Afternonn[/quote]

Title: Phase 2/3 Study of SM-88 in Patients with Metastatic Pancreatic Cancer
Session Title: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Virtual Session Date and Time: Sunday, January 17, 2021 3:30 PM ET – 4:15 PM ET
Virtual Session Location: ASCO poster website
Abstract Number: 321873[/quote]
Hsven't been able to access abstract. It's doable.

All I got so fat Gentlemen. Hoping we'll be able to access streaming video. Market closed Monday.

Peace

[RodeKroet]

human-api-raises-20m-series

btw, you.know I tend to share also competitive approaches (and I still think Colorcon got in bed with apdn ánd Trutag cos of me mentioning it as one of very few real competitors ;)

So here's one for cCTC counting:

portable-sequencer-ensures-cancer-cells-gone... also.not the first time I mentioned ONT... for what its worth.

Orangeman (from Belgium)

[RodeKroet]

What could be interesting is digging in some bigger possible schemes where Erik Schmidt and Adrees Horrowitz (and affiliates) are interested in, as they have recently injected Human API,real-health-announces-new-partnership-with-human-api-to-further-patient-engagement the clientcentered healthdata platform which has recently onboarded Cvleared4, APDN's recent partner in crime with safeCirkle (pool/surveillancetesting) AND diagnostics in their son to be CLEPapproved Lab...

I got some time this weekend. Tyme's playground (and the too technical stuuf is too new for me to expect a lot of dotconnecting, but I can try a bit...for you Shark I will try for sure).

Bullish to the max all !!!!


Oh, sorry Mike, but I do believe you shouldnt have aborted APDN completely...

[HANUMAN]

Please post as soon as you find something.

[mcsharkey]

Bet you 5 shares you can dig more info out than I can. Hayward was right in October 2019 where TYME has multiple connections to other pharmas and used in conjunction with them in cancer treatments. LINEARx cTC tech is a mutual interest to the all

[mcsharkey]

Thank You Hannuman! Tecnical poster on SM-88 efficacy supposed to be released today. Orelude to Monday. Ain't found it yet

[RodeKroet]

Seems both Tyme and APDN are in a compareable mood

[HANUMAN]

I think TYME will get a decent pop with Monday's presentation (already had good run up) but it seems to me that the best results would come in early diagnosed patients, rather than those who have already failed 2 or 3 drug regimes and are more or less circling the drain. Serious side effects are very low. So basically I think this will be a sell on news situation, as I expect the SP to drift back down. What interests me more now in the cancer field is CYDY's ongoing basket trial of their leronlimab, which anecdotally has brought patient's CTC's down to zero, thereby effectively cutting off mets. JMO, as my real skill is in orthopedics, particularly joint replacement. Best wishes Mike.

[mcsharkey]

Got 2 of 3 Oncology Articles, both covering our mainline SM-88 Clinical PANC clinical trials. This is self-sponsored going to be reported on with Monday's shin dig. The second and third reviews with a Dr. Ocean. Evidently positive. Hanuman, you're a clinician. See what you can make out of these:)

Trials Will Change the Metastatic Pancreatic Cancer Landscape
CAROLINE SEYMOUR
Friday, October 16, 2020
https://www.oncnursingnews.com/web-exclusives/clinical-trials-will-change-the-metastatic-pancreatic-cancer-landscape

Less Tumor Texture Variability From Baseline May Be Linked With Better Outcomes in PDAC
January 7, 2021
Hayley Virgil
https://www.onclive.com/view/less-tumor-texture-variability-from-baseline-may-be-linked-with-better-outcomes-in-pdac

[mcsharkey]

Rode, give us a shot. Here's my bread crumb trail.
E-mail exchange with our Investor Relations, Brian Gill today:

Mike #######
12:23 PM (6 hours ago)
Happy New Year Brian, the latest Corporate Presentation on TYME is still at November version. Can we expect an update before Monday? Prõspero Anø Nuevo

Brian Gill
12:36 PM (6 hours ago)
We will have a Jan 2021 version up soon.
********************************************
With new CEO, Richie Cunningham, format may be changed. However, on past presentations, the milestone chart was always on page 5. They update the presentation prior to most fundraising conferences and regularly click off the milestones made of the Fiscal Year.

Fiscal Year for TYME is April --> March. We're in Q4 at this time. FY22 begins on April 1st (ironically).

Due to COVID effecting our clinical trials, page 5 HEADLINE BANNER changed from
.....DELIVERING ON KEY MILESTONES POSITIONS FOR 2021
to
.....DELIVERING ON KEY MILESTONES POSITIONS FOR LONG-TERM SUCCESS

Other releases and Streaming Conference calls since November Presentation spoke of:
...(1) Beginning SM-19 Proof of Concept lab studies for COVID therapy NOW, 2021 Q4
...(2) Final report on PANC study 2022.
**********************************************************
List of Six Items that were to be finished by now, before COVID:

(1) Advance SM-88 clinical programs into other tumor types potentially including metastatic breast, reurrent prostate, and/or hematological cancers (luekimias)
(2) Present and/or publish final data from Part 1 of TYME-88-PANC study. This is self-sponsored and NOT our collaboration within PANCAN's study. THIS IS BEING PRESENTED ON MONDAY.
(3) Complete TMYE-19 Proof Of Concept study (COVID Therapy, not due till APRIL.
(4) Advance plans for TYME-18 enabling program, ahhh direct injection of SM-88-like serum into tumors. Not due till April.
(5) Complete enrollment in HopES Sarcoma study. April?
(6) Complete enrollment in TYME-88-PANC pivotal study. April
*********************************************************

Link to TYME's Corporate Presentations here https://www.tymeinc.com/investors/events-and-presentations/default.aspx

I think we're looking GREAT. But Who am I?

GLTUA

[RodeKroet]

With you Mickeyboy on your apdn thoughts...

[mcsharkey]

Wie Gehts Mick! Foose has the good technical analysis. This is the Fiscal Year's last quarter, so FY 2022 begins in Apr. Haven't checked for the release of a Corporate Presentatiom yet. Sheet 5 always charts out the milestones.

Been fairly SPOT ON.Two 2021 goals moved out from this Qtr to 2022 Q1 last issue due to COVID and trial delays. Also, expanding from focus on pancreatic to blood borne lukemias.

[sanderburwil]

Should see $5-7+ Asco and positive data. This is going to be huge

[mickyboy59]

Much more then 100%

Mike

I bought with an average around 90 cents.

Just because of you. Thank you very much !!!

what should I do now?.... tell me the direction

I really have no idea about the firm.

In the contrary to APDN, where I am still on board. We had good days also there...and I am convinced, that this is our year too....like here in TYME

regards

mickyboy

[mcsharkey]

Pretty damn pleased myself Chillin'. We have Foose and MikeyBoy on here that got damn near 100% probably over.

Looking for any data on Josepb Amhed Ewing's Sarcoma trial, and the expansion to blood-borne (leukemias). That would kick some ass. Posted a link to a small whitepapre released yesterday.

Short registrations have been dropping, and since this is heavily INSIDER OWNED, ahhhh, dunno why they'd pull them. Some data from ShortSqueeze:, damn that came out ragged use this LINK IF YOU'RE INTERESTED[/quote]

 
  
 Tyme Technologies Inc 
 $ 2.15 
 TYME 
 0.43 
 Short Squeeze Ranking™ 
 view 
 Short Interest Ratio (Days To Cover) 
 4.7 
 Short Percent of Float 
 3.22 % 
 Short % Increase / Decrease 
 -12 % 
 Short Interest (Shares Short) 
 2,040,000 
 Short Interest (Shares Short) - Prior 
 2,330,000 
 Daily Short Sale Volume 
 view 
 Daily Naked Short Selling List 
 view 
 % From 52-Wk High ($ 2.35) 
 -15.69% 
 % From 50-Day MA ($ 1.09) 
 57.19% 
 % From 200-Day MA ($ 1.18) 
 45.82% 
 % From 52-Wk Low ($ 0.10) 
 1620.00% 
 52-Week Performance 
 12.57% 
 Trading Volume - Today vs Avg 
 3804.68% 
 Trading Volume - Today 
 16,360,122 
 Trading Volume - Average 
 430,000 
 Shares Float 
 63,300,000 
 Market Cap. 
 $ 240,692,500 
 % Owned by Insiders 
 61.02% 
 % Owned by Institutions 
 16.26% 
 Exchange 
 NAS 
 Record Date 
 2020-DecB 
   
   
  
   
   
   
 Mission Statement 
   
 The mission of ShortSqueeze.com™ is to provide short interest stock market data and services, so our members will be better informed of short selling in the market, track shorts in stocks and gain from the advantages that can be achieved from this valuable market data. 
   
   
 

[ChillingPenguin]

Man it feels good being 35% profitable as of now!! This has taken too damn long, looking for over 100% for holding over a year

[RodeKroet]

Let cCTC be our umbilical cord my friend (that sounds odd)...still miss you. Apdn board is pretty quiet (near dead sometimes) without you, although I'm still the dotconnector (without audience ;) I get more attention from Judy Murrah than from anybody. Not complaining though!

Yes, thats good news ! Praying for ya and (depending on apdn's trend coming months) I might dip a toe in here as well)
GLTUA

[mcsharkey]

Rode! Got some good news for TYME with abstract released of our SM-88 therapy drug. AND, while not mentioning LINeaRX it does us the cCTC circulating Cancer Tumor Cell count through PCR as the metric proof.

Here'the link. https://meetinglibrary.asco.org/record/194388/abstract

American Society of Cancer Onthology shin dig coming up next Monday.

I turned over all my APDN into TYME Rode. Way underwater with it.

Blessings

[RodeKroet]

At least good to see Tyme doin well lately...
GLTUA ;)

[RodeKroet]

U in apdn Mike?

[mcsharkey]

PANCAN Clinical Trials Month Kick OFF. Possibilities associated with our rise.

This story doesn't list SM-88. Possible. Does get into low side-effects.
LINK TO Compelling story kicking off PANCAN CLINICAL TRIALS MONTH
And here's a BILL BOARD. Info Only Gentlemen

[ChillingPenguin]

Happy New Years McSharkey, we better get some good news in the upcoming meeting. Been holding this for too long, this year I'll sell it and move my money.

[mcsharkey]

HOT DAMN, this is a lot Better than effing around in politics. Thought the morning's was the return to normal.

Looking Good Chilling! Happy New Year ALL

[ChillingPenguin]

Hell yea, but at least the speculation will carry us up to the news.

[HANUMAN]

Would love to get a peek at that abstract. Someone must have.